Predictors of carotid atherosclerosis in systemic lupus erythematosus

Kathleen Maksimowicz-McKinnon1, Laurence S Magder, Michelle Petri

  • 1University of Pittsburgh, Pittsburgh, Pennsylvania, USA.

Insights

Systemic lupus erythematosus (SLE) patients have increased cardiovascular risk. Traditional risk factors, not SLE disease activity, are linked to carotid plaque in SLE patients.

Area of Science:

  • Cardiology
  • Rheumatology
  • Vascular Medicine

Background:

  • Patients with systemic lupus erythematosus (SLE) face a higher risk of cardiovascular and cerebrovascular events.
  • This increased risk persists even after accounting for traditional cardiovascular risk factors.

Purpose of the Study:

  • To investigate the association between traditional risk factors, novel cardiovascular markers, and SLE disease activity markers with the presence of significant carotid artery plaque.
  • To identify predictors of carotid plaque in patients with SLE.

Main Methods:

  • Carotid duplex imaging was performed on 605 patients with SLE from the Hopkins Lupus Cohort Study.
  • Clinical, laboratory, and serologic data were prospectively collected and analyzed.
  • Mean values of time-varying predictors were used in the analysis.

Main Results:

  • Carotid plaque prevalence strongly correlated with age.
  • After age adjustment, plaque was associated with male gender, hypertension, diabetes mellitus, elevated C3 levels, elevated serum creatinine, and high systolic blood pressure.
  • No strong association was found between carotid plaque and SLE disease activity or duration of SLE.

Conclusions:

  • Traditional cardiovascular risk factors are associated with carotid plaque in SLE patients.
  • SLE disease activity and duration do not appear to be strongly associated with carotid plaque.
  • An unidentified "lupus factor" independent of traditional risk factors may contribute to cardiovascular risk in SLE.
Abstract

Related Concept Videos

Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests01:27

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...